abstract: Mitochondrial DNA (mtDNA) mutations are a relatively common cause of progressive disorders that can be severe or even lifethreatening. There is currently no cure for these disorders; therefore recent research has been focused on attempting to prevent the transmission of these maternally inherited mutations. Here we highlight the challenges of understanding the transmission of mtDNA diseases, discuss current genetic management options and explore the use of germ-line reconstruction technologies to prevent mtDNA diseases. In particular we discuss their potential, indications, limitations and possible safety concerns.
Introduction
Pathogenic maternally inherited mitochondrial DNA (mtDNA) mutations are a frequent cause of severe human disease and are found in 0.5% of the population (Elliott et al., 2008) , with disease affecting at least one in 5000 individuals (Chinnery et al., 2000a, b; Schaefer et al., 2008) . Mitochondrial disorders are a clinically heterogeneous group and typically affect those organs and tissues with a high energy requirement such as the brain, skeletal muscle, heart and liver (McFarland et al., 2010) . Unlike nuclear DNA, every nucleated cell may contain hundreds or even thousands of copies of mtDNA. Patients with mitochondrial disease often exhibit heteroplasmy, the existence of a mixture of wild-type and mutant mtDNA within the same cell, tissue and individual. In general, the mutation load (% heteroplasmy) has to exceed a specific threshold before a biochemical defect is observed within the cell. This biochemical threshold is both tissue and mutation specific and is typically around 60%; however, levels as low as 10% have been reported for some mutations, making it difficult to precisely predict the phenotype based on mutation load (Chinnery et al., 1997; White et al., 1999a, b; Sacconi et al., 2008) . In addition environmental factors, such as physical exercise, tobacco smoking and exposure to certain medications, can impact on the clinical course of mitochondrial disease (Parikh et al., 2009) .
The presence of both heteroplasmy and a 'mtDNA bottleneck' during oogenesis has important implications in understanding mitochondrial disease transmission. Asymptomatic or oligosymptomatic mothers, with relatively low levels of heteroplasmy, may have children with much higher levels of mutant mtDNA. These children are subsequently affected by the mitochondrial disorder due to a biological sampling effect during the development of the female germline, resulting in a high degree of variability in the mutant load between individual oocytes from a single woman. The 'size' of this bottleneck appears to be mutation specific with selection also playing a role in some cases (Fan et al., 2008; Stewart et al., 2008; Cree et al., 2009) . This makes the genetic management of mitochondrial disease challenging.
Recently, technical advances in assisted reproductive technologies (ART) have resulted in the development of novel approaches to prevent the transmission of mitochondrial disease. The major focus of this technical review is to outline firstly, the current methods used for the genetic management of mtDNA disease and secondly, the novel approaches being developed, discussing their uses, limitations and ultimately their safety to ensure the health of offspring.
Current approaches
Oocyte donation is an ART commonly used in women of advanced maternal age. Oocyte donation is perhaps the easiest way to prevent the transmission of a maternally inherited mitochondrial disorder as the partners sperm is used to fertilize a donated oocyte . However its success is dependent on the availability of an egg donor with no genetic link to the prospective mother. This can be problematic in countries where there is a shortage of donated human oocytes or where couples wish to have a genetic link to their child.
Preimplantation genetic diagnosis (PGD) offers real potential for patients carrying heteroplasmic mutations, particularly those women with subclinical levels of mutant mtDNA (Poulton et al., 2009) . PGD is an established ART procedure that relies on standard IVF whereby cells are removed from an in vitro embryo. MtDNA mutant load is then assessed in one or two cells taken from a 6 to 10 cell stage embryo (Day 3) or, more recently, a small number of cells taken from the trophectoderm of Day 5 or Day 6 blastocysts (Treff et al., 2012) . Only those embryos deemed at low risk, with mutant load below the level of expression, are transferred back into the uterus. PGD is therefore most useful for mutations where accurate predictions can be made based on the mutation load in the mother, and for skewing mutations, such as the m.8993T.G mutation, where there is likely to be a disproportionately large number of oocytes with 0 and 100% mutant loads (White et al., 1999a, b; Steffann et al., 2006) . An important requirement for PGD is that the heteroplasmy levels of the biopsied material accurately reflect the mutant load of the whole embryo, and recent data suggest that this is indeed the case for both cleavage stage blastomeres and trophectoderm biopsies (Monnot et al., 2011; Treff et al., 2012) .
PGD has been successfully used for individuals with MELAS syndrome (mitochondrial encephalopathy, lactic acidosis and stroke-like episodes) and NARP (neuropathy, ataxia and retinitis pigmentosa) (Steffann et al., 2007; Poulton and Bredenoord, 2010; Sallevelt et al., 2013) .
The main challenge of using PGD for mitochondrial disease is determining the mutation levels below which embryos are suitable for transfer. This is particularly problematic for mutations where the severity of disease is not closely linked to the level of mutation, resulting in variable clinical manifestation. Difficulties also exist where mutant load changes with time and where the mutation is rare with little information regarding its transmission (Larsson et al., 1990; Rahman et al., 2001; Bredenoord et al., 2008) . Often these indications can limit the number of embryos available for transfer as clinicians will tend to be conservative in order to minimize the chance of having an affected offspring. However, a recent systematic review estimating the chance of having healthy offspring for heteroplasmic mitochondrial disorders following PGD has suggested a theoretical mutant load cut off of 18%, regardless of point mutation type. This cut-off is associated with a 95% or higher chance of the resulting baby being unaffected by mitochondrial disease (Hellebrekers et al., 2012) .
Despite the clear benefits provided by PGD, this technology cannot be used in women carrying homoplasmic mutations (where all mtDNA copies are mutated), as all resulting embryos would also be homoplasmic for the mutation. PGD is also of limited value for women with high mutant loads who display symptoms of the disease, particularly if they transmit mutant loads similar to their own, as they will be unlikely to produce embryos with low risk (Chinnery et al., 2000a, b; Brown et al., 2001; Bredenoord et al., 2009) . There is also the added complication that although the first generation may have low mutant load and be disease free, if a female embryo is transferred then, due to the mitochondrial bottleneck, the subsequent generation may be at risk. PGD may also be utilized in this generation to select an embryo with no mutant mtDNA in order to eliminate the risk in subsequent generations. This will result in elimination of the mutation in two generations; however, this can be limited to a single generation if a male embryo is selected.
The ultimate success of PGD can be measured by the birth of healthy children with little or no mutant mtDNA. Surprisingly there are very few follow-up reports of these children. However, close examination of a family affected with MELAS reported by Treff and co-workers suggests that caution is warranted (Treff et al., 2012) . Following PGD from a trophectoderm biopsy at Day 5, a male embryo with a mutant load of 12% was selected for transfer. This embryo implanted and resulted in a live birth. The initial report was cautiously optimistic and suggested a healthy child with a buccal cell heteroplasmy level of 15% at 1 month of age. However, more recent follow-up reports suggest that the child has multi-system problems and a mutant load of 46% in blood and 42% in urine at 18 months (Wallace and Chalkia, 2013; Mitalipov et al., 2014) . This suggests that further follow-up studies of children born following PGD for mitochondrial mutations should be encouraged.
The limitations of PGD, such as those outlined above, have led to the development of strategies aimed at eliminating the transmission of mitochondrial mtDNA mutations rather than reducing the risk of having affected offspring.
Cytoplasmic transfer
As with many other embryological tools available in human assisted reproduction, cytoplasmic transfer (also called ooplasmic transfer) was originally established in the 1980s as an experimental tool to elucidate the role of cytoplasmic determinants on embryonic development in mice (Muggleton-Harris et al., 1982) . Although mitochondrial transfer was not the primary objective, cytoplasmic transfer has entered assisted reproduction to counteract the decrease in developmental competence of oocytes collected from aged oocyte donors or those with repeated fertilization failure. It was suggested that oocyte competence, and therefore embryo development, may be enhanced by transferring ooplasm from unfertilized oocytes donated from young donors with proven fertility into oocytes collected from aged donors ( Fig. 1a ) (Malter and Cohen, 2002; Levy et al., 2004) . Approximately 5-15% of donor ooplasm is transferred to the recipient oocyte (Barritt et al., 2001a, b) . This ooplasm contains mRNAs, proteins, mitochondria and other organelles (Cohen et al., 1997) .
Analysis of the mtDNA from offspring produced using this procedure has established that generally the donor contributed only a small amount of mtDNA. However, in a few cases the donor mtDNA was able to proliferate to levels higher than the 5 -15% donated (Brenner et al., 2004) . This means that offspring produced from this procedure are heteroplasmic for both the donor and recipient mtDNA genomes.
Cytoplasmic transfer has been used in several ART cycles mainly in the late 1990s and predominantly in the USA, leading to the birth of over 30 babies (Soini et al., 2006) . However, the effective benefit of this technology was never fully proved, and its safety was questioned by many, particularly the uncertainties regarding the effects of mixing together two mitochondrial populations and creating a heteroplasmic population of mitochondria (Cummins, 2001; Acton et al., 2007) . Indeed, follow-up on the pregnancies and offspring born using this technology revealed two cases of Turner's syndrome (45, XO) out of 17 fetuses and one case of pervasive developmental disorder, a sex-linked autism-related disorder (Barritt et al., , 2001a Brenner et al., 2000; Levy et al., 2004) . Due to uncertainties regarding whether these abnormalities are the result of mitochondrial heteroplasmy exerting an epigenetic effect, asynchrony between the donor and recipient oocyte maturation, or the result of the manipulations themselves, the main regulatory agency in the USA, the Food and Drug Administration, banned the procedure in 2001 until a clinical study could be conducted to determine its safety. Despite these recommendations no such study was performed. However, this technology is still commercially available in IVF clinics in numerous countries worldwide.
Cytoplasmic transfer has not, to date, been used to prevent the transmission of a mitochondrial disorder. Whilst it is theoretically possible that the proportions of mutant mtDNA to wild-type mtDNA can be altered by transferring large numbers of highly purified donor mtDNA, given the health concerns highlighted above it is unlikely that this procedure will be the method of choice for the prevention of transmission of mitochondrial disease Ferreira et al., 2010) . Cytoplasmic transfer has therefore been largely abandoned and replaced by alternative approaches to avoid the transmission of mtDNA diseases, mainly by moving the nuclear genetic material from oocytes with mutated mtDNA into enucleated oocytes containing wildtype mtDNA.
Figure 1 (a) Schematic diagram of cytoplasmic transfer. Cytoplasm containing wild-type (white) mitochondria is extracted from a 'healthy' mature donor oocyte and injected into the oocyte of the recipient containing mutated (red) mitochondria. This creates heteroplasmic oocytes containing a mixture of mutated mtDNA and the supplemented wild-type mtDNA. (b) Schematic diagram of GV transfer. This technique involves enucleating both the donor and recipient oocytes. The genetic material from the immature oocyte (at the germinal vesicle (GV) stage), containing the mutated (red) mitochondria is then transferred into an enucleated oocyte containing wild-type (white) mitochondria. The GV is then electrofused, the oocyte matured and fertilized by either IVF or ICSI. The levels of mtDNA heteroplasmy are determined by how much mutant mtDNA is carried over during the GV transfer procedure. (c) Schematic diagram of MII transfer. The metaphase II (MII) spindles are removed from the mature oocytes of the carrier containing the mutated (red) mitochondria and fused into the enucleated mature oocyte containing healthy, wild-type (white) mtDNA. The reconstructed mature oocyte can then be fertilized by either IVF or ICSI. The levels of mtDNA heteroplasmy are again determined by the amount of mutant mtDNA carried over in the karyoplast. (d) Schematic diagram of pronuclear (PN) transfer. Following fertilization the two pronuclei are removed from both the donor and recipient zygotes. The pronuclei taken from the zygote with mutated (red) mtDNA are then transferred and fused into a zygote with wild-type (white) mtDNA. The levels of heteroplasmy are dependent on the amount of mutant mtDNA carried over during this procedure.
Gene replacement for mitochondrial disease
Nuclear genome transfer
The available techniques for nuclear transfer between oocytes/zygotes are germinal vesicle (GV) transfer, metaphase II (MII) spindle transfer and pronuclear (PN) transfer. GV and MII spindle transfer use unfertilized oocytes, whereas PN transfer uses zygotes (Brown et al., 2006; Craven et al., 2010) .
Oocytes from women aged 35 years and over are known to have higher rates of aneuploidy. Increased rates of aneuploidy are one of the main causes of infertility in older women. Therefore, GV transfer was originally devised to avoid age-related aneuploidies in oocytes from older woman. This procedure involves transferring the nuclear genetic material, aspirated with a bevelled pipette, from an immature oocyte at the GV stage, into a previously enucleated oocyte donated from a young donor (Fig. 1b) . The GV (karyoplast) is transferred into the perivitelline space and electro-fused by application of a single or multiple (2 -3) short (40/60 microsecond) direct current pulses in non-electrolytic medium. The fusion rate using this procedure has a high efficiency. This treatment was first used in 1999 with a good proportion of reconstructed human oocytes successfully entering MII arrest (up to 80%). However, in this study no indications were provided on the developmental capacity of the reconstructed oocytes . In a more recent study (Tanaka et al., 2009a, b) , the nuclei from 35 oocytes from older woman were transferred into enucleated oocytes from younger donors. In this study 28% developed to the blastocyst stage which was much higher than the 'untreated' group which showed 3% development. All blastocysts were karyotypically normal. However, data are still lacking on the post-implantation developmental competence of these embryos, the degree of mtDNA carryover and the health outcomes of offspring created using this technology (Tanaka et al., 2009a, b) .
Full developmental data are available in both mice and rabbit model systems Li et al., 2001; Takeuchi et al., 2004) . In an elegant study by Takeucki et al. (2004) GV stage oocytes had their mitochondria damaged by irradiation and consequently were incapable of maturation. The idea was to 'rescue' these oocytes using GV transfer. This procedure was successful and resulted in normal embryonic development, with live birth rates being equivalent to non-manipulated controls. The resulting offspring were normal, even in adulthood, and exhibited normal fertility (Takeuchi et al., 2004) . Whilst these results are apparently optimistic, indicating that the manipulation is not having a detrimental effect on embryo development, confirmation in other model organisms is limited and there is a lack of data with regards to the amount of mtDNA carryover following these procedures, particularly in humans. A further complication of this technology is the requirement for in vitro maturation (IVM) of the oocytes, and although highly successful in mice, there remains no efficient, optimized procedure for IVM in humans. As such IVM is still regarded as an experimental technique in the clinic largely due to suboptimal rates of fertilization and poor embryo quality/developmental competence.
The second method of nuclear transfer is MII spindle transfer. Most of the mammalian mature oocytes are arrested at MII of the meiotic division. The removal of the metaphase plate of MII oocytes is a common manipulation required for cloning mammals by somatic cell nuclear transfer. There is therefore a wealth of technical detail available on this procedure. The MII chromosomes are localized with different techniques, such as Hoechst staining and UV irradiation, treatment with cytoskeleton inhibitors or differential interference contrast (Nomarsky/Offmann optics). The method of choice largely depends on the species (Iuso et al., 2013) . In the case of human oocytes, the clear ooplasm allows an easy localization of the meiotic spindle by polarized light microscopy (Keefe et al., 2003) . The chromosome-spindle complex is removed from the oocyte with mutated mtDNA for transfer into the donor oocyte. It is then fused to an enucleated oocyte with wild-type mtDNA (Fig. 1c) . The reconstructed oocyte is then fertilized with sperm from the intending father. MII transfer is less invasive than GV transfer as the condensed chromosomes can be easily aspirated in the pipette with a minimal amount of cytoplasm; therefore the amount of mitochondrial transfer is small. The fusion between the karyoplast and cytoplast is normally induced by electro-fusion or inactivated Sendai virus (Tarkowski and Balakier, 1980; Wang et al., 2001; Tanaka et al., 2009a, b) with satisfactory outcomes.
Early attempts using this technology were largely unsuccessful, with poor rates of fertilization and poor embryo development. However, recent methodological advances have allowed proof of principle experiments to be conducted in primates (Tachibana et al., 2009 (Tachibana et al., , 2010 . In this novel study by Tachibana et al. (2009) , reconstructed MII oocytes were capable of normal fertilization, normal embryo development and four live and healthy offspring were produced. These results indicate that in monkey, MII spindle-complexes can be isolated with high efficiency and transferred into enucleated oocytes. MtDNA carryover was undetectable; however, we have to treat these results with caution given that the detection level of the assay was 3% (Tachibana et al., 2009; St John and Campbell, 2010) . It is therefore possible that there are low levels of mtDNA carryover using this procedure and these issues have to be investigated in more detail before the procedure can be used clinically (Spikings et al., 2006) .
Human studies have not shown quite as much promise, with around half of manipulated oocytes showing fertilization failure (Tachibana et al., 2013) . However those that were fertilized did proceed to the blastocyst stage of development. The high levels of fertilization failure following manipulation were thought to be due to premature oocyte activation. This suggests that human MII oocytes are extremely sensitive to manipulation of the spindle. Premature oocyte activation can lead to karyotype abnormalities; therefore it is imperative that the protocols are further optimized to ensure safety prior to this procedure being offered in the clinic.
The final technique is pronuclear (PN) transfer. PN transfer uses standard IVF procedure to fertilize both the patient and donor's oocyte. Shortly after fertilization the male and female pronuclei are visualized. These 2 pronuclei are removed with a little cytoplasm (karyoplast) using a similar basic procedure as MII spindle transfer. The karyoplast is then injected into the perivitelline space of an enucleated wild-type zygote (Fig. 1d) . Fusion is by electric pulse or inactivated Sendai viruses. PN transfer was the first manipulation ever carried out on a mammalian embryo and was initially used to demonstrate the differential contribution to development provided by the parental genomes (McGrath and Solter, 1984) . Pre-clinical assays were successfully modelled in mice and showed that the reconstructed zygotes can develop to the blastocyst stage, implant and develop to full term (Kono and Tsunoda, 1988; Sato et al., 2005) . The first applications of PN transfer to prevent mitochondrial related diseases in human are just starting to appear. In a pioneering study, Craven et al. (2010) transferred pro-nuclei between abnormally fertilized human zygotes and showed limited mtDNA carryover (,2%). These manipulated zygotes were able to progress to the blastocyst stage. Interestingly, the levels of nuclear donor mtDNA (representing the patient sample) varied amongst individual blastomeres suggesting altered mtDNA segregation; however, it is currently unclear whether this is a result of the procedure or the abnormal status of the zygotes (Craven et al., 2010) .
So, which stage we will elect for avoiding the transmission of mitochondrial diseases in assisted reproduction?
The number of oocytes retrievable from a stimulated patient wishing to benefit from mitochondrial replacement is limited; hence the technique chosen must be highly efficient. Pragmatically, the developmental capacity of the operated oocytes/zygotes has to be high, and the amount of mtDNA carryover must be kept to a minimum, or even better, eliminated completely. So, which of the genomic replacement approaches available offers better chances?
GV, MII and PN transfer all rely on the micromanipulation-assisted aspiration of the genome enveloped by a small fraction of cytoplasm, its transfer into the perivitelline space of the recipient enucleated oocyte/ zygote followed by the electro/virus induced fusion. These operations are relatively easy in human oocytes/zygotes for GV, MII and PN, as the chromosomes are easily identifiable and the fusion rate is normally very high. While the three options are technically similar, they differ significantly from a cell cycle point of view.
With regards to GV transfer, the need for cytoskeleton inhibitors and the micromanipulation procedure itself interrupts the metabolic coupling between the corona radiata and the oocyte. The interplay between the oocyte and its surrounding somatic cells is critical for maintaining meiotic arrest (Wigglesworth et al., 2013) . It is therefore likely to foresee problems in the control of meiotic progression, and if we consider that IVM in human oocytes is far from optimal, a GV manipulated oocyte might struggle to enter the MII stage. Lastly, IVF itself might also be compromised, given the crucial role played by granulosa cells in activating spermatozoa, although this may be overcome by ICSI (Jin et al., 2013) .
Reports of GV transfer between human immature oocytes have been published; however, they have never managed to become robust and reproducible procedures Takeuchi et al., 2001) .
As opposed to GV oocytes, MII oocytes are ready to be fertilized. However, zona pellucida piercing with MII oocytes may result in polyspermic fertilization. This can be easily overcome through the use of ICSI. The original concern about the capacity of manipulated oocytes to correctly complete the second meiosis have largely been overcome, first in the mouse Cheng et al., 2003) and, more recently, in primates (Tachibana et al., 2009) . However, the high levels of fertilization failure in MII manipulated human oocytes warrant further investigation (Tachibana et al., 2013) .
On this basis, MII and PN transfer are, in our opinion, better candidates for mitochondrial replacement. Based solely on the developmental competence of the resulting embryos, we tend to favour PN transfer although further safety and efficacy data are required as outlined below.
If we consider the second requirement, the minimization of mtDNA carryover, it is important to look at mitochondrial dynamics during oocyte maturation and following fertilization. Mitochondria undergo redistribution throughout meiotic progression, a process that has been documented in human oocytes (Van Blerkom et al., 2000; Liu et al., 2010) . In GV stage oocytes mitochondria are concentrated in the perinuclear space, often associated with lipid vesicles (Wilding et al., 2001) . Therefore there is huge potential for a significant amount of patient DNA to be transferred into the donor oocyte following GV transplantation. During meiotic progression, mitochondria scatter in the cytoplasm, where they tend to concentrate in the inner cytoplasm. At the PN stage, mitochondria are again concentrated in a peri-nuclear position, particularly during pronuclear opposition (Van Blerkom et al., 2000) . Hence, it is likely that there will be less carryover of patient mtDNA in MII karyoplasts compared with PN transfer.
The published data on mitochondrial replacement using PN and MII transfer confirm this view. The proportion of mtDNA copies carried over has been estimated to be 1% in MII (Paull et al., 2013) , versus 8% (Craven et al., 2010) in PN transfer, which reflects the mitochondria dynamics described above. In both methods the number of mtDNA copies carried over along with the karyoplast is barely detectable at the blastocyst stage and apparently disappears in embryonic and differentiated cells derived from mitochondrial replaced blastocysts (Paull et al., 2013) . Moreover, Craven et al. have demonstrated that the proportion of carryover mitochondria might be reduced to ,2% using careful manipulation (Craven et al., 2010) . Whilst in an ideal scenario we would wish to completely eliminate the carryover of patient mtDNA, a recent study by Samuels et al. (2013) which modelled the inheritance of mtDNA heteroplasmy, and is therefore applicable to all technologies discussed, has suggested that carryover of ,5% dramatically reduces the chance of mitochondrial disease occurring in successive generations. However further studies may be necessary to determine whether there is preferential replication of mutant mtDNA and differential segregation of mutant mtDNA across different tissues following these procedures.
MII and PN transfer also appear to be equivalent with regards to their developmental competence. Some of the human data are biased by the fact that abnormal fertilized zygotes were used as a genome donor (Craven et al., 2010) ; therefore similar experiments using normally fertilized embryos will be invaluable. However, using MII transfer, a recent study has shown that 62% of fertilized oocytes developed to the blastocyst stage following the manipulation. This value is comparable to values obtained in clinics; therefore the results are optimistic (Tachibana et al., 2013) .
Conclusion
At present PGD offers real potential and is the method of choice for risk reduction particularly in women with low levels of mtDNA heteroplasmy. However its successful use is dependent on the generation of high-quality embryos with low mutant load, making it unsuitable for some patients.
MII and PN transfer are new techniques that are, in our opinion, suitable for the prevention of mtDNA diseases provided the issues of safety and efficacy are thoroughly addressed. Neither technique guarantees a complete elimination of the patient mtDNA; therefore, the coordinated mito-nuclear interactions and the phenotypic penetrance of mtDNA heteroplasmy need to be further investigated in animal models derived from manipulated oocytes/zygotes before these techniques are transferred to the clinic (Haites and R, 2011) . In addition the issue of tissuespecific segregation effects needs to be addressed to exclude the possibility of one mitochondrial haplogroup being favoured over another. This can be examined in embryos, embryonic stem cells and their differentiation derivatives, ideally from animal models and also from human embryos generated by these procedures. Given the variability between different mtDNA mutations, in vitro assessments should be modelled on a mutation-specific basis.
The safety control should not be limited to early embryonic stages but instead extended to adulthood, preferably in successive generations. The available data in humans refer only to early embryo development and/or stem cells isolated from the operated oocytes (Paull et al., 2013) , which is clearly not sufficient to deem these methods safe. Therefore safety testing of blastocysts and stem cells should involve investigating the early morphokinetic events (using time lapse microscopy), and examination of the chromosomal constitution of the blastocysts in addition to examinations of the transcriptome, genome, proteome and epigenome. Long-term follow-up in other animal models is required to provide full empirical proof of principle of the lack of adverse effects following mitochondrial replacement (Spikings et al., 2006; Craven et al., 2011; Reinhardt et al., 2013 ). This will be particularly important in animal models carrying pathogenic mutations, for example in mice, where the transgenerational effects can be studied.
Given the lack of data with regards to compatibility of the two mitochondrial genomes, it would be prudent to initially select haplogroup matched donors in early clinical studies. PGD should be implemented to ensure complete mtDNA replacement and to check for chromosomal integrity prior to transfer. Patients should be followed up during pregnancy and any product of conception should be subjected to detailed analysis if any spontaneous abortion arises. Long-term follow-up of any children resulting from these procedures will be necessary.
The follow-up is fundamental not only for the mtDNA carryover issues but also for the embryological consequences of the manipulations and genome transfer itself. MII and PN transfer are highly invasive manipulations that may affect the integrity of the nuclear DNA. It is impossible to replace the removed MII or PN exactly in the previously occupied position. If cytoplasmic determinants, or polarity, are present in human oocytes, this might create problems in itself. The issue of predetermined gradients in mammalian oocytes is controversial, with reports in support (Piotrowska and Zernicka-Goetz, 2002 ) and against its presence (Hiiragi and Solter, 2004) . However, emerging data suggest that early blastomeres show obvious epigenetic differences as early as the 4 cells stage (Piotrowska-Nitsche et al., 2005; Torres-Padilla et al., 2007) . Whether these differences arise due to the differential segregation of oocyte/ zygotic cytoplasm gradients or other mechanisms remains to be elucidated. Therefore it will be necessary to assess mitochondrial functionality, content, and the distribution of mitochondria both before and after these manipulations. Induced pluripotent stem cell studies may be used to complement this approach.
In humans long-term follow-up of children born following embryo biopsy is lacking; however, a recent report of 995 children born following Day 3 biopsy for PGD suggests that the embryo biopsy procedure does not affect the health outcome of children at 2 months of age (Desmyttere et al., 2012) . However, in mice, published reports and unpublished data from our laboratory confirm that there are long-term effects from invasive manipulations such as blastomere biopsy. These manipulations produce dramatically altered embryo architecture which can result in a predisposition to metabolic and psychological diseases, such as obesity and autism (Yu et al., 2009) . Detailed analysis of epigenetic modifications following MII spindle transfer and PN transfer would therefore also be recommended as these manipulations could potentially lead to developmental defects or manifest themselves later in life, again pointing to the need for long-term follow-up of animal models. In addition it will be necessary to investigate whether these effects are exacerbated following ageing or increased stress.
We believe it would be wise to test potential side effects on animal models that share similar major developmental milestones and reproductive physiology to humans. For example, sheep or bovine models could be used before clinical application of these invasive reproductive technologies. This approach would be preferable to the retrospective investigations of safety that are common to ART.
Despite the technical and ethical challenges of these approaches, mitochondrial transfer holds great promise to enable women carrying mtDNA mutations to have a child who is genetically related to them without transmitting the mutated mtDNA, thus preventing the transmission of mtDNA disease.
